Will this new discovery bring us one step closer to ‘universal’ cancer treatment?

New research performed by the researchers at Cardiff University has discovered a new type of T-cell receptor (TCR) for killing cancer cells.

This new TCR targets a molecule called MR1 and kills the cancerous cell bearing it.
While the study is still in its early stages, it has already modified the existing therapies against stubborn cancer cells.
This novel cancer treatment has proven to kill different types of cancer such as lung, bone, prostate, skin, colon, breast, cervical, kidney, and blood cells.
The technique has currently been performed safely on animals, scientists are testing its efficacy in humans.
Professor Awen Gallimore, the leading head of the Wales Cancer Research Center believes that this finding may lay the foundation of a universal T-cell medicine for identification and treatment of different cancer cells
3 Key Points
  1. A recent study has unmasked a new type of TCR that targets MR1 molecules to kill cancer cells.
  2. The new TCR treatment has successfully killed multiple types of human cancer cells in animal models and is currently under being evaluated for safety in humans.
  3. The new TCR modality may form the basis of a universal T medicine that can identify and treat different kinds of cancer.

Professor Andrew Sewell, lead author of the study said, “This is truly exciting and potentially a great step forward for the accessibility of cancer immunotherapy.”

Article source: http://bit.ly/2TwMyoZ
Image source: http://bit.ly/2QjmBIH

#Pharmaceutical, #DrugDevelopment, #Healthcare, #ClinicalTrial

P.S. Want to learn more about cancer research? Always stay informed by getting summarized articles straight to your inbox for FREE. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria ACTide @ Medical device trials

Medical Device Trials – Virtual Experience

Read more
Nubilaria ACTide @ Direct to Patient digital experience

Direct-to-Patient and Virtual Clinical Trials – Digital Experience

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems